Fullerenol/iron nanocomposite modulates doxorubicin-induced cardiotoxicity
Authorized Users Only
2017
Authors
Seke, MarianaPetrović, Danijela
Labudović-Borović, Milica
Jović, Danica S.
Borišev, Ivana
Kanacki, Zdenko
Zikić, Dragan
Đorđević, Aleksandar N.
Conference object (Published version)
Metadata
Show full item recordAbstract
Background: Doxorubicin is a first line cancer chemotherapeutic. Unfortunately, its clinical use is limited by its cardiotoxicity. It is known that iron overload aggravates anthracycline toxicity. Fullerenol is a 1 nm size molecule and in aqueous solutions is in the form of polyanionic nanoparticles, which enables them to serve as a good carrier of positively charged ions such as Fe2+. Fullerenol’s antioxidant activity through scavenging free radicals has already been proved in different biological systems.
Methods: The aim of our study was to investigate the effects of the fullerenol/iron nanocomposite as a pretreatment to doxorubicin on the rat’s heart in comparison to doxorubicin alone. After the 24h-treatment, adult male Wistar rats were sacrificed and hearts were collected for ultrastructural and qRT-PCR analysis. Considering the ability of doxorubicin to induce oxidative stress, and the fullerenol’s capability to mitigate it, we had chosen to monitor gene expression of enzymes i...nvolved in antioxidant defense.
Results: Ultrastructural study revealed that in the group pretreated with the nanocomposite prior to doxorubicin application cardiomyocytes were with preserved morphology and the structure of intercalated discs. On the other hand, the heart tissues of animals treated with doxorubicin alone were significantly more damaged. Intensive interstitial edema was observed, as well as vacuolization of cardiomyocytes, hypercontraction of sarcomeres, mitochondria of irregular shapes. qRT-PCR results have shown that neither treatment with doxorubicin alone nor the pretreatment with the nanocomposite did cause significant increase in mRNA levels of catalase and superoxide dismutase.
Conclusions: Our results indicate that the fullerenol/iron nanocomposite applied as pretreatment to doxorubicin induces less damage to the hearth tissue in comparison to doxorubicin alone.
Source:
Annals of Oncology, 2017, 28, Supplement 5Funding / projects:
- Functional, Functionalized and Advanced Nanomaterials (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-45005)
Note:
- 42nd European-Society-for-Medical-Oncology Congress (ESMO), Sep 08-12, 2017, Madrid, Spain
Collections
Institution/Community
VinčaTY - CONF AU - Seke, Mariana AU - Petrović, Danijela AU - Labudović-Borović, Milica AU - Jović, Danica S. AU - Borišev, Ivana AU - Kanacki, Zdenko AU - Zikić, Dragan AU - Đorđević, Aleksandar N. PY - 2017 UR - https://vinar.vin.bg.ac.rs/handle/123456789/7182 AB - Background: Doxorubicin is a first line cancer chemotherapeutic. Unfortunately, its clinical use is limited by its cardiotoxicity. It is known that iron overload aggravates anthracycline toxicity. Fullerenol is a 1 nm size molecule and in aqueous solutions is in the form of polyanionic nanoparticles, which enables them to serve as a good carrier of positively charged ions such as Fe2+. Fullerenol’s antioxidant activity through scavenging free radicals has already been proved in different biological systems. Methods: The aim of our study was to investigate the effects of the fullerenol/iron nanocomposite as a pretreatment to doxorubicin on the rat’s heart in comparison to doxorubicin alone. After the 24h-treatment, adult male Wistar rats were sacrificed and hearts were collected for ultrastructural and qRT-PCR analysis. Considering the ability of doxorubicin to induce oxidative stress, and the fullerenol’s capability to mitigate it, we had chosen to monitor gene expression of enzymes involved in antioxidant defense. Results: Ultrastructural study revealed that in the group pretreated with the nanocomposite prior to doxorubicin application cardiomyocytes were with preserved morphology and the structure of intercalated discs. On the other hand, the heart tissues of animals treated with doxorubicin alone were significantly more damaged. Intensive interstitial edema was observed, as well as vacuolization of cardiomyocytes, hypercontraction of sarcomeres, mitochondria of irregular shapes. qRT-PCR results have shown that neither treatment with doxorubicin alone nor the pretreatment with the nanocomposite did cause significant increase in mRNA levels of catalase and superoxide dismutase. Conclusions: Our results indicate that the fullerenol/iron nanocomposite applied as pretreatment to doxorubicin induces less damage to the hearth tissue in comparison to doxorubicin alone. C3 - Annals of Oncology T1 - Fullerenol/iron nanocomposite modulates doxorubicin-induced cardiotoxicity VL - 28 IS - Supplement 5 DO - 10.1093/annonc/mdx390.057 UR - https://hdl.handle.net/21.15107/rcub_vinar_7182 ER -
@conference{ author = "Seke, Mariana and Petrović, Danijela and Labudović-Borović, Milica and Jović, Danica S. and Borišev, Ivana and Kanacki, Zdenko and Zikić, Dragan and Đorđević, Aleksandar N.", year = "2017", abstract = "Background: Doxorubicin is a first line cancer chemotherapeutic. Unfortunately, its clinical use is limited by its cardiotoxicity. It is known that iron overload aggravates anthracycline toxicity. Fullerenol is a 1 nm size molecule and in aqueous solutions is in the form of polyanionic nanoparticles, which enables them to serve as a good carrier of positively charged ions such as Fe2+. Fullerenol’s antioxidant activity through scavenging free radicals has already been proved in different biological systems. Methods: The aim of our study was to investigate the effects of the fullerenol/iron nanocomposite as a pretreatment to doxorubicin on the rat’s heart in comparison to doxorubicin alone. After the 24h-treatment, adult male Wistar rats were sacrificed and hearts were collected for ultrastructural and qRT-PCR analysis. Considering the ability of doxorubicin to induce oxidative stress, and the fullerenol’s capability to mitigate it, we had chosen to monitor gene expression of enzymes involved in antioxidant defense. Results: Ultrastructural study revealed that in the group pretreated with the nanocomposite prior to doxorubicin application cardiomyocytes were with preserved morphology and the structure of intercalated discs. On the other hand, the heart tissues of animals treated with doxorubicin alone were significantly more damaged. Intensive interstitial edema was observed, as well as vacuolization of cardiomyocytes, hypercontraction of sarcomeres, mitochondria of irregular shapes. qRT-PCR results have shown that neither treatment with doxorubicin alone nor the pretreatment with the nanocomposite did cause significant increase in mRNA levels of catalase and superoxide dismutase. Conclusions: Our results indicate that the fullerenol/iron nanocomposite applied as pretreatment to doxorubicin induces less damage to the hearth tissue in comparison to doxorubicin alone.", journal = "Annals of Oncology", title = "Fullerenol/iron nanocomposite modulates doxorubicin-induced cardiotoxicity", volume = "28", number = "Supplement 5", doi = "10.1093/annonc/mdx390.057", url = "https://hdl.handle.net/21.15107/rcub_vinar_7182" }
Seke, M., Petrović, D., Labudović-Borović, M., Jović, D. S., Borišev, I., Kanacki, Z., Zikić, D.,& Đorđević, A. N.. (2017). Fullerenol/iron nanocomposite modulates doxorubicin-induced cardiotoxicity. in Annals of Oncology, 28(Supplement 5). https://doi.org/10.1093/annonc/mdx390.057 https://hdl.handle.net/21.15107/rcub_vinar_7182
Seke M, Petrović D, Labudović-Borović M, Jović DS, Borišev I, Kanacki Z, Zikić D, Đorđević AN. Fullerenol/iron nanocomposite modulates doxorubicin-induced cardiotoxicity. in Annals of Oncology. 2017;28(Supplement 5). doi:10.1093/annonc/mdx390.057 https://hdl.handle.net/21.15107/rcub_vinar_7182 .
Seke, Mariana, Petrović, Danijela, Labudović-Borović, Milica, Jović, Danica S., Borišev, Ivana, Kanacki, Zdenko, Zikić, Dragan, Đorđević, Aleksandar N., "Fullerenol/iron nanocomposite modulates doxorubicin-induced cardiotoxicity" in Annals of Oncology, 28, no. Supplement 5 (2017), https://doi.org/10.1093/annonc/mdx390.057 ., https://hdl.handle.net/21.15107/rcub_vinar_7182 .